Stakeholder Opinions: Hematopoietic Stem Cell Transplantation - In need of further research and development

리서치사	Datamonitor
발행일	2009년 04월	상품코드	85285
페이지 정보	68 pages
가격	US $ 3,800 ￦ 4,527,700 PDF by E-mail (Single User License) US $ 9,500 ￦ 11,319,200 PDF by E-mail (Global Site License)

한글목차
영문목차
관련자료

영문목차

Abstract

Introduction

Hematopoietic stem cell transplantation (HSCT) has evolved considerably over the past 50 years, driven by developments in stem cell sources, donor identification and conditioning regimens. Nowadays, it has a range of applications, including the treatment of certain hematologic malignancies. However, further research efforts are required to expand its use and improve patient outcomes.

Scope of this research

Usage data for HSCT and overview of the procedure in terms of stem cell donors, stem cell sources, and conditioning regimens
Discussion of the use of drug therapy in HSCT conditioning and in the management of complications, including current research and development trends
Unmet needs and research priorities in the field of HSCT
Stakeholder opinions based on qualitative interviews with key opinion leaders from the US and EU

Research and analysis highlights

The use of HSCT has been increasing in the past decades, driven by developments in stem cell sources and conditioning regimens. However, it seems to remain an underutilized treatment, with many patients being referred for a transplant only at advanced stages of disease, where cure is less likely.

The development of reduced-intensity conditioning (RIC) regimens is one of the major advances in the field of HSCT. Current research evaluating monoclonal antibodies and radioimmunotherapy may help increase the efficacy and specificity of conditioning therapy.

The effective management of graft-versus-host disease (GVHD) is an unmet need in the field of HSCT. The availability of better preclinical models, prognostic tools, and effective therapies are considered R&D priorities. Monoclonal antibodies may have a role in the treatment of GVHD but further research is required to investigate their potential.

Key reasons to purchase this research

Obtain analysis of current HSCT usage data and trends in the use of stem cell donors, stem cell sources, and conditioning regimens
Obtain an overview of current drug use in HSCT conditioning and in the management of HSCT complications, including graft-versus-host disease
Identify unmet needs and research priorities in the field of HSCT

EXECUTIVE SUMMARY

Scope of analysis
Datamonitor insight into hematopoietic stem cell transplantation
Contributing experts
Related reports
Upcoming reports

HEMATOPOIETIC STEM CELL TRANSPLANTATION OVERVIEW

Definition
Overview of the hematopoietic stem cell transplantation procedure
Use and applications of hematopoietic stem cell transplantation
Types of stem cell transplants
- Stem cell donors
- Stem cell sources
- Conditioning

Mortality and survival data

PHARMACOLOGIC USE

Conditioning regimens
- Myeloablative regimens
- Reduced-intensity conditioning
- Conditioning by type of hematologic malignancy
- Research & development in the conditioning field

Prophylaxis and treatment of hematopoietic stem cell transplantation complications
- Early complications
- Late complications

Other areas of research & development
- Augmentation of the graft-versus-tumor (GVT) effect
- Expansion of allogeneic HSCT to solid tumors

UNMET NEEDS & RESEARCH PRIORITIES

Key findings
Unmet needs and research priorities in hematopoietic stem cell transplantation
- HSCT remains an underutilized treatment
- Relapse remains the main cause of death after HSCT
- HSCT is in need of an overall refinement
- The effective management of graft-versus-host disease is considered a priority

BIBLIOGRAPHY

APPENDIX

TABLES

Table: Hematopoietic stem cell transplantation: definitions
Table: Donor types for allogeneic hematopoietic stem cell transplantation
Table: Comparison of stem cell sources for hematopoietic stem cell transplantation
Table: Reduced-intensity conditioning (RIC) and nonmyeloablative regimens: mode of action
Table: Three-year survival rates for patients with acute myeloid leukemia and diffuse large B-cell lymphoma
Table: Examples of radiation-based conditioning regimens used in hematopoietic stem cell transplantation
Table: Examples of chemotherapy-based conditioning regimens used in hematopoietic stem cell transplantation
Table: Examples of reduced-intensity conditioning regimens used in hematopoietic stem cell transplantation
Table: Examples of conditioning regimens used in hematopoietic stem cell transplantation by type of hematologic malignancy
Table: Investigation of Rituxan and Campath in regimens used in hematopoietic stem cell transplantation conditioning
Table: Investigation of anti-CD20 radioimmunotherapy in hematopoietic stem cell transplantation conditioning
Table: Early complications of hematopoietic stem cell transplantation
Table: Selected drugs available for use in the prophylaxis of acute graft-versus-host disease
Table: Selected drugs investigated in the treatment of steroid-refractory acute graft-versus-host disease
Table: Drugs/therapies in company-sponsored Phase III development for graft-versus-host disease as their primary indication, 2009
Table: Late complications of hematopoietic stem cell transplantation
Table: Selected drugs investigated in the treatment of steroid-refractory chronic graft-versus-host disease

FIGURES

Figure: The normal hematopoiesis process
Figure: Overview of the hematopoietic stem cell transplantation procedure
Figure: The applications of autologous and allogeneic hematopoietic stem cell transplantation
Figure: Main indications for hematopoietic stem cell transplantation in 2007, according to EBMT data
Figure: Indications for allogeneic hematopoietic stem cell transplantation worldwide in 2005, according to CIBMTR data
Figure: Annual number of hematopoietic stem cell transplantations worldwide, 1970 2006, according to CIBMTR data
Figure: Stem cell sources for allogeneic and autologous transplants in patients over 20 years of age, 1997 2006, according to CIBMTR data
Figure: The use of myeloablative and reduced-intensity conditioning regimens in allogeneic transplants, 1998 2006 according to CIBMTR data
Figure: Age distribution of patients receiving allogeneic transplants by conditioning regimen intensity, 2005 06, according to CIBMTR data
Figure: Causes of death after transplantations, 2001 06, according to CIBMTR data
Figure: Unmet needs and research priorities in hematopoietic stem cell transplantation